DCTH Delcath Systems, Inc. - Common Stock
$17,21
Kurs · Aug 19, 2026
Fundamentaldaten per Aug 6, 2026
52W-Spanne
$8–$17
98% of range
Analystenbewertung
BUY
12 analysts
Kursziel
$24
+39% upside
P/E (TTM)
245.9
ROE
2.5%
Nettogewinnmarge
3.2%
Über Delcath Systems, Inc. - Common Stock Unternehmensübersicht von Wikipedia
Delcath Systems, Inc. is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion (PHP) is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally.
Mehr lesen
Delcath Systems, Inc. (NASDAQ: DCTH) is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion (PHP) is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally (e.g. specialty drugs, melphalan (trade name Alkeran), busulfan, capecitabine).
## Phase III melanoma trial enrolling
University of Pittsburgh Medical Center
National Cancer Institute in Bethesda, Maryland
Albany Medical Center in Albany, New York
John Wayne Cancer Center in Santa Monica, California
Moffitt Cancer Center in Tampa, Florida
Morristown Memorial Hospital in Morristown, New Jersey
Providence Cancer Center in Portland, Oregon
St. Luke's Cancer Center of Bethlehem, Pennsylvania
Swedish Medical Center in Englewood, Colorado
University of Maryland Medical Center in Baltimore, Maryland
University of Texas Medical Branch in Galveston, Texas
Quelle: Wikipedia (Englisch), CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
DCTH Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$17.21
Marktkapitalisierung
$597M
P/E (TTM)
245.9
EPS (TTM)
$0.07
Umsatz (TTM)
$85M
Dividendenrendite
—
ROE
2.5%
Verschuldungsgrad
—
52W-Spanne
$8 – $17
DCTH Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Configure
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz & Nettoergebnis
$85M
2016-12-31
→
2025-12-31
EPS
$0.07
2017-12-31
→
2025-12-31
Freier Cashflow
$21M
2018-12-31
→
2025-12-31
Margen
3.2%
2022-12-31
→
2025-12-31
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
Kennzahl
5-Jahres-Trend
DCTH
Peer-Median
P/E (TTM)
245.9
32.9
P/S (TTM) (K/V (TTM))
7.0
4.6
P/B (K/B)
5.4
3.5
Price / FCF (Kurs / FCF)
28.5
—
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
Kennzahl
5-Jahres-Trend
DCTH
Peer-Median
Gross Margin (Bruttogewinnmarge)
86.2%
66.5%
Operating Margin (Betriebsgewinnmarge)
0.77%
—
Net Profit Margin (Nettogewinnmarge)
3.2%
-9.8%
ROA
2.7%
-8.8%
ROE
2.5%
-15.5%
ROIC
0.46%
—
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
Kennzahl
5-Jahres-Trend
DCTH
Peer-Median
Current Ratio (Liquiditätsgrad)
10.9
4.8
Quick Ratio
5.0
—
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
Kennzahl
5-Jahres-Trend
DCTH
Peer-Median
Revenue YoY (Umsatz YoY)
129.1%
—
Revenue CAGR 3Y (Umsatz CAGR 3J)
215.3%
—
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
Kennzahl
5-Jahres-Trend
DCTH
Peer-Median
DCTH Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
KAUF
12 Analysten
- Starker Kauf 3 25,0%
- Kauf 8 66,7%
- Halten 1 8,3%
- Verkauf 0 0,0%
- Starker Verkauf 0 0,0%
12-Monats-Kursziel
5 Analysten · 2026-08-18
Median
$22.00
Mittelwert
$24.00
← Unter allen Zielen
$17.21
Tief
$21.00
Hoch
$32.00
Median-Ziel
$22.00
+27,8%
Mittelwert-Ziel
$24.00
+39,5%
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
0.05%
| Zeitraum | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|
| 30. Juni 2026 | $0.07 | $-0.09 | 0.16% |
| 31. März 2026 | $-0.03 | $-0.09 | 0.06% |
| 31. Dezember 2025 | $-0.05 | $-0.06 | 0.01% |
| 30. September 2025 | $0.02 | $0.02 | -0.00% |
| 30. Juni 2025 | $0.07 | $0.03 | 0.04% |
| 31. März 2025 | $0.03 | $0.02 | 0.01% |
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| DCTH | $350M | 144.3 | 129.1% | 3.2% | 2.5% | 86.2% |
| SIBN | $861M | -44.8 | 20.2% | -9.4% | -10.9% | 79.6% |
| SSII | — | -94.7 | 105.7% | — | — | — |
| ANGO | $479M | -13.0 | 9.5% | -11.5% | -21.2% | 54.6% |
| TCMD | $651M | 35.4 | 12.5% | 5.8% | 9.2% | 75.9% |
| NPCE | $518M | -23.4 | 25.1% | -21.5% | -111.6% | 77.2% |
| CLPT | $402M | -15.2 | 17.8% | -69.1% | -106.9% | 61.4% |
| SGHT | $424M | -10.7 | -3.1% | -49.7% | -57.4% | 86.2% |
| SENS | $228M | -3.3 | 56.9% | -196.0% | -88.7% | 44.7% |
| ABT | $250.18B | 33.7 | 5.7% | 14.7% | 13.1% | — |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung 18
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $85M | $37M | $2M | $3M | $4M | · | · | · | $3M | $2M | $2M | $1M | |
| Cost of Revenue | $12M | $6M | $635.0K | $686.0K | $671.0K | $640.0K | $719.0K | $1M | $701.0K | $550.0K | $462.0K | $291.0K | |
| Gross Profit | $73M | $31M | $1M | $2M | $3M | $1M | $861.0K | $2M | $2M | $1M | $1M | $778.0K | |
| R&D Expense | $29M | $14M | $18M | $19M | $14M | $11M | $9M | $20M | $10M | $8M | $6M | $4M | |
| SG&A Expense | $44M | $30M | $22M | $17M | $14M | $11M | $11M | $10M | $10M | $9M | $10M | $16M | |
| Operating Expenses | $73M | $43M | $40M | $36M | $27M | $22M | $21M | $29M | $20M | $18M | $16M | $20M | |
| Operating Income | $660.0K | $-12M | $-38M | $-34M | $-25M | $-21M | $-20M | $-27M | $-18M | $-16M | $-15M | $-19M | |
| Interest Expense | · | · | · | · | · | · | · | · | $22M | $14M | $67.0K | · | |
| Interest Income | · | · | · | · | · | · | · | · | · | $17.0K | $9.0K | $5.0K | |
| Other Non-op | $-70.0K | $-30.0K | $-59.0K | $30.0K | $68.0K | $154.0K | $2.0K | $51.0K | $-41.0K | $17.0K | $9.0K | $-24.0K | |
| Pretax Income | $4M | $-26M | $-48M | $-37M | $-26M | $-24M | $-9M | $-19M | $-45M | $-18M | $-15M | $-17M | |
| Income Tax | $810.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $3M | $-26M | $-48M | $-37M | $-26M | $-24M | $-9M | $-19M | $-45M | $-18M | $-15M | $-17M | |
| EPS (Basic) | $0.08 | $-0.93 | $-2.94 | $-4.12 | $-3.59 | $-8.35 | $-342.83 | $-0.72 | $-3250.00 | · | $-0.91 | $-1.84 | |
| EPS (Diluted) | $0.07 | $-0.93 | $-2.94 | $-4.12 | $-3.59 | $-8.35 | $-342.83 | $-0.72 | $-3250.00 | · | $-0.91 | $-1.84 | |
| Shares (Basic) | 35,821,157 | 28,511,393 | 16,229,931 | 8,864,615 | 7,145,754 | 2,897,827 | 25,900 | 26,705,375 | 14,039 | · | 16,161,687 | 9,452,050 | |
| Shares (Diluted) | 39,919,557 | 28,511,393 | 16,229,931 | 8,864,615 | 7,145,754 | 2,897,827 | 25,900 | 26,705,375 | 14,039 | · | 16,161,687 | 9,452,050 | |
| EBITDA | $660.0K | $-12M | $-38M | $-34M | $-25M | $-21M | $-20M | $-27M | · | · | $-15M | $-19M |
Bilanz 25
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $43M | $32M | $13M | $8M | $23M | $29M | $10M | $3M | $4M | $4M | $13M | $20M | |
| Receivables | $12M | $11M | $241.0K | $366.0K | $44.0K | $57.0K | $21.0K | $585.0K | $317.0K | $403.0K | $277.0K | $174.0K | |
| Inventory | $10M | $7M | $3M | $2M | $1M | $855.0K | $654.0K | $858.0K | $1M | $660.0K | $757.0K | $349.0K | |
| Prepaid Expense | $6M | $3M | $1M | $2M | $3M | $3M | $2M | $898.0K | $700.0K | $698.0K | $960.0K | $974.0K | |
| Other Current Assets | · | · | · | · | · | · | · | · | · | · | · | $222.0K | |
| Current Assets | $120M | $74M | $37M | $16M | $31M | $32M | $13M | $6M | $8M | $34M | $15M | $22M | |
| PP&E (Net) | $3M | $2M | $1M | $1M | $1M | $1M | $735.0K | $925.0K | $1M | $1M | $1M | $2M | |
| PP&E (Gross) | $8M | $7M | $6M | $6M | $6M | $6M | $5M | $5M | $5M | $5M | $5M | $6M | |
| Accum. Depreciation | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $4M | $4M | $4M | $4M | $4M | |
| Total Assets | $124M | $77M | $39M | $18M | $33M | $35M | $14M | $7M | $9M | $35M | $16M | $24M | |
| Accounts Payable | $3M | $961.0K | $1M | $2M | $638.0K | $2M | $5M | $8M | $4M | $594.0K | $284.0K | $748.0K | |
| Accrued Liabilities | $8M | $5M | $5M | $5M | $4M | $5M | $7M | $8M | $3M | $3M | $2M | $4M | |
| Current Liabilities | $11M | $6M | $16M | $15M | $6M | $10M | $16M | $18M | $8M | $36M | $6M | $5M | |
| Capital Leases | $835.0K | $933.0K | $0 | · | $207.0K | $450.0K | $197.0K | $0 | · | · | · | · | |
| Other Non-current Liabilities | $628.0K | $766.0K | $840.0K | $1M | $207.0K | · | $0 | $628.0K | $395.0K | $604.0K | $820.0K | $1M | |
| Total Liabilities | $12M | $8M | $23M | $24M | $21M | $13M | $21M | $22M | $8M | $37M | $7M | $6M | |
| Long-term Debt | · | $0 | $10M | $16M | · | · | · | · | · | · | · | · | |
| Common Stock | $347.0K | $331.0K | $228.0K | $100.0K | $79.0K | $60.0K | $1.0K | $0 | $2.0K | $0 | $14.0K | $97.0K | |
| Paid-in Capital | $639M | $600M | $521M | $452M | $433M | $417M | $365M | $329M | $326M | $278M | $270M | $265M | |
| Retained Earnings | $-529M | $-532M | $-505M | $-457M | $-421M | $-395M | $-371M | $-344M | $-325M | $-279M | $-261M | $-247M | |
| Treasury Stock | · | · | · | · | · | · | · | $0 | $51.0K | $51.0K | $51.0K | $51.0K | |
| AOCI | $575.0K | $82.0K | $135.0K | $-83.0K | $18.0K | $-104.0K | $28.0K | $50.0K | $42.0K | $-41.0K | $-8.0K | $20.0K | |
| Stockholders' Equity | $111M | $69M | $16M | $-6M | $12M | $22M | $-6M | $-15M | $678.0K | $-1M | $9M | $18M | |
| Liabilities + Equity | $124M | $77M | $39M | $18M | $33M | $35M | $14M | $7M | $9M | $35M | $16M | $24M | |
| Shares Outstanding | 34,691,671 | 33,061,002 | 22,761,554 | 10,046,571 | 7,906,728 | 5,996,101 | 67,091 | 14,715 | 228,139 | 11,750 | 1,360,239 | 9,708,841 |
Cashflow 12
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Deferred Tax | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $23M | $-19M | $-31M | $-25M | $-23M | $-23M | $-24M | $-15M | $-15M | $-14M | $-16M | $-16M | |
| CapEx | $2M | $559.0K | $58.0K | $209.0K | $143.0K | $782.0K | $24.0K | $76.0K | $524.0K | $258.0K | $170.0K | $44.0K | |
| Investing Cash Flow | $-27M | $-981.0K | $-20M | $-209.0K | $-143.0K | $-782.0K | $-24.0K | $-76.0K | $-524.0K | · | · | · | |
| Net Debt Issued | · | $-11M | $-6M | · | · | · | · | · | · | · | · | · | |
| Stock Issued | $481.0K | $250.0K | $123.0K | $0 | $2M | $230.0K | $0 | $11M | · | · | · | · | |
| Stock Repurchased | $6M | $0 | · | · | · | · | · | · | · | · | · | · | |
| Net Stock Activity | $-6M | $250.0K | $123.0K | · | $2M | $230.0K | $0 | · | · | · | · | · | |
| Financing Cash Flow | $15M | $39M | $52M | $10M | $21M | $42M | $30M | $13M | $-11M | · | · | · | |
| Net Change in Cash | $11M | $20M | $874.0K | $-15M | $-2M | $19M | $7M | $-2M | $-26M | $-8M | $-8M | $-11M | |
| Taxes Paid | $2M | $0 | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $21M | $-19M | $-31M | $-25M | $-23M | $-24M | $-24M | $-15M | · | · | $-17M | $-16M |
Rentabilität 8
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.2% | 83.4% | 69.2% | 74.8% | · | · | · | · | · | · | 73.6% | 72.8% | |
| Operating Margin | 0.77% | -33.4% | -1849.0% | -1245.0% | · | · | · | · | · | · | -870.6% | -1805.8% | |
| Net Margin | 3.2% | -70.9% | -2308.9% | -1342.7% | · | · | · | · | · | · | -841.7% | -1625.9% | |
| Pretax Margin | 4.1% | -70.9% | -2308.9% | -1342.7% | · | · | · | · | · | · | -841.7% | · | |
| EBITDA Margin | 0.77% | -33.4% | -1849.0% | -1245.0% | · | · | · | · | · | · | -870.6% | -1805.8% | |
| ROA | 2.7% | -45.8% | -168.8% | -143.2% | -75.7% | -98.9% | -84.3% | -244.4% | · | · | -74.5% | -57.1% | |
| ROE | 2.5% | -68.2% | -235.5% | 657.5% | -216.7% | -190.6% | 70.5% | 194.1% | · | · | -109.9% | -72.0% | |
| ROIC | 0.46% | -18.1% | -242.0% | 577.8% | -205.3% | -96.5% | 313.2% | · | · | · | -176.8% | · |
Liquidität & Solvenz 2
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.9 | 12.0 | 2.3 | 1.1 | 5.2 | 3.2 | 0.8 | 0.3 | · | · | 2.3 | 4.8 | |
| Quick Ratio | 5.0 | 7.0 | 0.8 | 0.5 | 3.8 | 2.9 | 0.6 | 0.2 | · | · | 2.0 | 4.5 |
Effizienz 3
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.9 | 0.6 | 0.1 | 0.1 | · | · | · | · | · | · | 0.1 | 0.0 | |
| Inventory Turnover | 1.4 | 1.2 | 0.2 | 0.4 | 0.6 | 0.8 | 1.0 | 1.0 | · | · | 0.8 | 0.5 | |
| Receivables Turnover | 7.5 | 6.7 | 6.8 | 13.3 | · | · | · | · | · | · | 7.7 | 4.1 |
Wachstumsraten 2
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 129.1% | 1701.7% | -24.1% | -23.5% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 215.3% | 118.7% | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM) 10
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $85M | $37M | $2M | $3M | $4M | $3M | $3M | $3M | $3M | $2M | $2M | $1M | |
| Net Income TTM | $3M | $-26M | $-48M | $-37M | $-26M | $-24M | $-9M | $-19M | $-45M | $-18M | $-15M | $-17M | |
| Market Cap | $350M | $398M | $95M | $28M | $61M | $107M | $1M | $2.01B | · | · | · | · | |
| P/E | 144.3 | -12.9 | -1.4 | -0.9 | -2.2 | -2.1 | -0.1 | -272.2 | · | · | · | · | |
| P/S | 4.1 | 10.7 | 45.9 | 10.5 | 17.2 | 34.8 | 0.5 | 649.3 | · | · | · | · | |
| P/B | 3.2 | 5.8 | 6.0 | -4.9 | 5.1 | 4.9 | -0.2 | -134.2 | · | · | · | · | |
| P / Tangible Book | 3.2 | 5.8 | 6.0 | · | 5.1 | 4.9 | · | · | · | · | · | · | |
| P / Cash Flow | 15.6 | -21.3 | -3.0 | -1.1 | -2.7 | -4.7 | -0.1 | -136.1 | · | · | · | · | |
| P / FCF | 16.7 | -20.7 | -3.0 | -1.1 | -2.7 | -4.5 | -0.1 | -135.4 | · | · | · | · | |
| Earnings Yield | 0.69% | -7.7% | -70.7% | -114.4% | -46.3% | -46.6% | -1613.3% | -0.37% | · | · | · | · |
Gewinn- und Verlustrechnung 16
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29M | $25M | $21M | $21M | $24M | $20M | $15M | $11M | $8M | $3M | $539.0K | $434.0K | $495.0K | $597.0K | $638.0K | $906.0K | |
| Cost of Revenue | $3M | $4M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $903.0K | $171.0K | $133.0K | $150.0K | $181.0K | $238.0K | $235.0K | |
| Gross Profit | $26M | $21M | $18M | $18M | $21M | $17M | $13M | $10M | $6M | $2M | $368.0K | $301.0K | $345.0K | $416.0K | $400.0K | $671.0K | |
| R&D Expense | $10M | $10M | $9M | $8M | $7M | $5M | $3M | $4M | $3M | $4M | $5M | $5M | $4M | $5M | $4M | $4M | |
| SG&A Expense | $13M | $13M | $11M | $10M | $11M | $11M | $7M | $7M | $7M | $9M | $7M | $6M | $5M | $4M | $4M | $5M | |
| Operating Expenses | $24M | $23M | $20M | $18M | $18M | $16M | $10M | $11M | $10M | $13M | $12M | $11M | $8M | $9M | $8M | $9M | |
| Operating Income | $2M | $-2M | $-2M | $-388.0K | $3M | $642.0K | $3M | $-1M | $-4M | $-10M | $-11M | $-11M | $-8M | $-8M | $-8M | $-8M | |
| Other Non-op | $-17.0K | $-58.0K | $-7.0K | $-33.0K | $-34.0K | $4.0K | $-53.0K | $35.0K | $10.0K | $-22.0K | $-73.0K | $-5.0K | $6.0K | $13.0K | $27.0K | $26.0K | |
| Pretax Income | $3M | $-908.0K | $-1M | $375.0K | $3M | $1M | $-3M | $2M | $-14M | $-11M | · | · | · | · | · | · | |
| Income Tax | $491.0K | $162.0K | $562.0K | $-455.0K | $508.0K | $195.0K | $0 | $0 | $0 | $0 | · | · | · | · | · | · | |
| Net Income | $3M | $-1M | $-2M | $830.0K | $3M | $1M | $-3M | $2M | $-14M | $-11M | $-11M | $-20M | $-7M | $-9M | $-8M | $-9M | |
| EPS (Basic) | $0.07 | $-0.03 | $-0.05 | $0.02 | $0.08 | $0.03 | $-0.06 | $0.06 | $-0.48 | $-0.45 | $-0.45 | $-1.14 | $-0.58 | $-0.77 | $-0.82 | $-0.96 | |
| EPS (Diluted) | $0.07 | $-0.03 | $-0.05 | $0.02 | $0.07 | $0.03 | $-0.06 | $0.06 | $-0.48 | $-0.45 | $-0.45 | $-1.14 | $-0.58 | $-0.77 | $-0.82 | $-0.96 | |
| Shares (Basic) | 35,891,915 | 36,021,210 | -70,991,574 | 36,383,277 | 35,786,813 | 34,642,641 | -53,478,825 | 28,738,307 | 28,364,731 | 24,887,180 | -25,719,196 | 17,863,078 | 12,463,665 | 11,622,384 | -16,732,137 | 9,215,786 | |
| Shares (Diluted) | 39,761,480 | 36,021,210 | -79,911,141 | 40,056,814 | 40,262,764 | 39,511,120 | -57,086,190 | 32,345,672 | 28,364,731 | 24,887,180 | -25,719,196 | 17,863,078 | 12,463,665 | 11,622,384 | -16,732,137 | 9,215,786 | |
| EBITDA | $2M | $-2M | · | $-388.0K | $3M | $642.0K | · | $-1M | $-4M | $-10M | · | $-11M | $-8M | $-8M | · | $-8M |
Bilanz 23
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $48M | $41M | $43M | $42M | $34M | $13M | $32M | $8M | $15M | $12M | $13M | $40M | $15M | $24M | $8M | $10M | |
| Receivables | $16M | $14M | $12M | $14M | $16M | $14M | $11M | $7M | $4M | $2M | $241.0K | $205.0K | $127.0K | $458.0K | $366.0K | $537.0K | |
| Inventory | $12M | $10M | $10M | $11M | $11M | $7M | $7M | $7M | $6M | $4M | $3M | $3M | $2M | $2M | $2M | $2M | |
| Prepaid Expense | $7M | $7M | $6M | $7M | $6M | $4M | $3M | $1M | $1M | $1M | $1M | $3M | $2M | $2M | $2M | $2M | |
| Current Assets | $131M | $120M | $120M | $121M | $113M | $84M | $74M | $29M | $31M | $34M | $37M | $46M | $19M | $29M | $16M | $18M | |
| PP&E (Net) | $4M | $4M | $3M | $3M | $2M | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | |
| PP&E (Gross) | $9M | $9M | $8M | $8M | $8M | $7M | $7M | $7M | $7M | $6M | $6M | $6M | $6M | $6M | $6M | $6M | |
| Accum. Depreciation | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | |
| Total Assets | $137M | $125M | $124M | $124M | $117M | $87M | $77M | $32M | $34M | $36M | $39M | $48M | $21M | $31M | $18M | $20M | |
| Accounts Payable | $4M | $3M | $3M | $2M | $5M | $2M | $961.0K | $937.0K | $3M | $1M | $1M | $753.0K | $966.0K | $2M | $2M | $3M | |
| Accrued Liabilities | $9M | $7M | $8M | $6M | $6M | $4M | $5M | $6M | $4M | $4M | $5M | $5M | $6M | $7M | $5M | $5M | |
| Current Liabilities | $13M | $11M | $11M | $8M | $10M | $5M | $6M | $22M | $12M | $13M | $16M | $14M | $11M | $13M | $15M | $14M | |
| Capital Leases | $2M | $815.0K | $835.0K | $855.0K | $877.0K | $906.0K | $933.0K | $963.0K | $989.0K | $1M | $0 | · | · | · | · | · | |
| Other Non-current Liabilities | $327.0K | $615.0K | $628.0K | $582.0K | $578.0K | $896.0K | $766.0K | $563.0K | $632.0K | $962.0K | $840.0K | $1M | $1M | $1M | $1M | $1M | |
| Total Liabilities | $16M | $12M | $12M | $9M | $12M | $7M | $8M | $23M | $30M | $21M | $23M | $23M | $21M | $25M | $24M | $25M | |
| Long-term Debt | · | · | · | · | · | · | · | $2M | $4M | $7M | $10M | · | · | · | $16M | · | |
| Common Stock | $346.0K | $344.0K | $347.0K | $353.0K | $350.0K | $334.0K | $331.0K | $280.0K | $279.0K | $254.0K | $228.0K | $197.0K | $153.0K | $101.0K | $100.0K | $86.0K | |
| Paid-in Capital | $648M | $642M | $639M | $641M | $632M | $610M | $600M | $536M | $534M | $530M | $521M | $519M | $473M | $453M | $452M | $442M | |
| Retained Earnings | $-527M | $-530M | $-529M | $-527M | $-528M | $-530M | $-532M | $-528M | $-530M | $-516M | $-505M | $-494M | $-474M | $-466M | $-457M | $-447M | |
| AOCI | $258.0K | $571.0K | $575.0K | $875.0K | $592.0K | $381.0K | $82.0K | $11.0K | $8.0K | $157.0K | $135.0K | $-59.0K | $-64.0K | $-64.0K | $-83.0K | $-57.0K | |
| Stockholders' Equity | $121M | $113M | $111M | $115M | $105M | $80M | $69M | $9M | $4M | $15M | $16M | $25M | $-242.0K | $-13M | $-6M | $-5M | |
| Liabilities + Equity | $137M | $125M | $124M | $124M | $117M | $87M | $77M | $32M | $34M | $36M | $39M | $48M | $21M | $31M | $18M | $20M | |
| Shares Outstanding | 34,636,252 | 34,465,087 | 34,691,671 | 35,308,939 | 34,955,974 | 33,436,612 | 33,061,002 | 28,019,599 | 27,931,393 | 25,439,319 | 22,761,554 | 19,688,991 | 15,250,469 | 10,046,571 | 10,046,571 | 8,597,682 |
Cashflow 10
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $6M | $857.0K | $8M | $5M | $7M | $2M | $-1M | $-4M | $-4M | $-10M | $-8M | $-9M | $-10M | $-4M | $-7M | $-5M | |
| CapEx | $503.0K | $570.0K | $550.0K | $459.0K | $398.0K | $140.0K | $229.0K | $216.0K | $101.0K | $13.0K | $19.0K | $-1.0K | $40.0K | $0 | $0 | $68.0K | |
| Investing Cash Flow | $-504.0K | $-571.0K | $-561.0K | $-466.0K | $-415.0K | $-25M | $-15M | $-697.0K | $10M | $5M | $-20M | $1.0K | $-40.0K | $0 | $0 | $-68.0K | |
| Stock Issued | $0 | $389.0K | $0 | $243.0K | $0 | $238.0K | $0 | $175.0K | $0 | $75.0K | $0 | $76.0K | $0 | $47.0K | $0 | $0 | |
| Stock Repurchased | $11.0K | $3M | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Net Stock Activity | · | $-3M | · | · | · | $238.0K | · | · | · | $75.0K | · | · | · | $47.0K | · | · | |
| Financing Cash Flow | $962.0K | $-2M | $-6M | $3M | $15M | $3M | $40M | $-2M | $-3M | $4M | $1.0K | $35M | $7.0K | $17M | $5M | $5M | |
| Net Change in Cash | $6M | $-2M | $2M | $7M | $22M | $-20M | $24M | $-6M | $3M | $-886.0K | $-28M | $26M | $-10M | $12M | $-2M | $-372.0K | |
| Taxes Paid | · | · | $228.0K | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | $287.0K | · | · | · | $2M | · | · | · | $-10M | · | · | · | $-4M | · | · |
Rentabilität 8
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 89.8% | 85.0% | · | 87.2% | 86.3% | 85.6% | · | 85.4% | 80.4% | 71.2% | · | 69.3% | 69.7% | 69.7% | · | · | |
| Operating Margin | 8.2% | -6.6% | · | -1.9% | 10.7% | 3.2% | · | -11.2% | -50.4% | -327.4% | · | -2432.3% | -1615.6% | -1394.5% | · | · | |
| Net Margin | 9.2% | -4.3% | · | 4.0% | 11.2% | 5.4% | · | 16.6% | -176.9% | -354.0% | · | -4686.6% | -1455.0% | -1507.5% | · | · | |
| Pretax Margin | 10.8% | -3.6% | · | 1.8% | 13.3% | 6.4% | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | 8.2% | -6.6% | · | -1.9% | 10.7% | 3.2% | · | -11.2% | -50.4% | -327.4% | · | -2432.3% | -1615.6% | -1394.5% | · | · | |
| ROA | 2.1% | -1.0% | · | 1.1% | 3.6% | 1.7% | · | 4.7% | -50.0% | -33.3% | · | -60.0% | -34.2% | -31.1% | · | -31.1% | |
| ROE | 2.4% | -1.1% | · | 1.4% | 4.9% | 2.2% | · | 11.2% | -695.8% | -1439.2% | · | -208.9% | 466.5% | 229.3% | · | -262.5% | |
| ROIC | 1.7% | -1.7% | · | -0.75% | 2.1% | 0.68% | · | · | · | · | · | · | · | · | · | · |
Liquidität & Solvenz 2
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.8 | 11.2 | · | 15.1 | 10.9 | 16.0 | · | 1.3 | 2.6 | 2.5 | · | 3.3 | 1.8 | 2.2 | · | 1.3 | |
| Quick Ratio | 4.8 | 5.2 | · | 6.9 | 4.8 | 5.1 | · | 0.7 | 1.5 | 1.0 | · | 2.9 | 1.3 | 1.8 | · | 0.7 |
Effizienz 3
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.1 | · | 0.0 | 0.0 | 0.0 | · | · | |
| Inventory Turnover | 0.3 | 0.4 | · | 0.3 | 0.4 | 0.5 | · | 0.4 | 0.3 | 0.3 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.8 | 1.8 | · | 2.0 | 2.5 | 2.6 | · | 3.1 | 4.0 | 3.1 | · | 1.2 | 1.8 | 1.9 | · | · |
Bewertung (TTM) 10
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $99M | $89M | · | $76M | $63M | $42M | · | $23M | $12M | $5M | · | $2M | $3M | $3M | · | · | |
| Net Income TTM | $5M | $4M | · | $6M | $-8M | $-22M | · | $-43M | $-52M | $-48M | · | $-45M | $-35M | $-37M | · | $-35M | |
| Market Cap | $436M | $320M | · | $380M | $475M | $426M | · | $253M | $234M | $121M | · | $80M | $89M | $58M | · | $28M | |
| P/E | 96.8 | 103.1 | · | 59.7 | -42.5 | -15.2 | · | -4.5 | -3.2 | -1.6 | · | -1.2 | -1.6 | -1.4 | · | -0.8 | |
| P/S | 4.4 | 3.6 | · | 5.0 | 7.6 | 10.2 | · | 11.2 | 19.8 | 26.0 | · | 32.8 | 31.8 | 21.6 | · | · | |
| P/B | 3.6 | 2.8 | · | 3.3 | 4.5 | 5.3 | · | 29.5 | 55.8 | 8.3 | · | 3.2 | -367.4 | -4.4 | · | -5.2 | |
| P / Tangible Book | 3.6 | 2.8 | · | 3.3 | 4.5 | 5.3 | · | 29.5 | 55.8 | 8.3 | · | 3.2 | · | · | · | · | |
| P / Cash Flow | · | 373.2 | · | · | · | 193.2 | · | · | · | -12.7 | · | · | · | -13.5 | · | · | |
| P / FCF | · | 1114.4 | · | · | · | 206.3 | · | · | · | -12.6 | · | · | · | -13.5 | · | · | |
| Earnings Yield | 1.0% | 0.97% | · | 1.7% | -2.4% | -6.6% | · | -22.3% | -31.7% | -61.6% | · | -85.2% | -60.9% | -70.8% | · | -132.5% |
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
Gewinn- und Verlustrechnung
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Umsatz | $85M | $37M | $2M | $3M | $4M |
| Bruttogewinnmarge % | 86.2% | 83.4% | 69.2% | 74.8% | — |
| Betriebsgewinnmarge % | 0.77% | -33.4% | -1849.0% | -1245.0% | — |
| Nettoergebnis | $3M | $-26M | $-48M | $-37M | $-26M |
| Verwässerte EPS | $0.07 | $-0.93 | $-2.94 | $-4.12 | $-3.59 |
Bilanz
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Liquiditätsgrad | 10.9 | 12.0 | 2.3 | 1.1 | 5.2 |
| Quick Ratio | 5.0 | 7.0 | 0.8 | 0.5 | 3.8 |
Cashflow
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| Freier Cashflow | $21M | $-19M | $-31M | $-25M | $-23M |
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
📊
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das ➕ neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Institutionelle Eigentümer (13F) 140 Einreicher · $188.2M gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 27 (-4 vs. Vorquartal) | 17 (-3 vs. Vorquartal) | 40 (+6 vs. Vorquartal) | 30 (-8 vs. Vorquartal) | -56K |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| Rosalind Advisors, Inc. | $41.551.898 | 3.300.389 | 22,08% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $15.375.500 | 1.221.247 | 8,17% | Aktien |
| VANGUARD GROUP INC | $14.879.573 | 1.473.225 | 7,91% | Aktien |
| Propel Bio Management, LLC | $10.971.681 | 871.460 | 5,83% | Aktien |
| STATE STREET CORP | $8.552.135 | 679.280 | 4,55% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $7.923.535 | 629.139 | 4,21% | Aktien |
| ALGERT GLOBAL LLC | $7.311.114 | 580.708 | 3,89% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $7.130.611 | 566.371 | 3,79% | Aktien |
| Divisadero Street Capital Management, LP | $6.292.432 | 499.796 | 3,34% | Aktien |
| ExodusPoint Capital Management, LP | $4.530.940 | 359.884 | 2,41% | Aktien |
| Private Wealth Advisors, LLC | $3.913.765 | 310.863 | 2,08% | Aktien |
| Simplify Asset Management Inc. | $3.333.454 | 264.770 | 1,77% | Aktien |
| BlackRock, Inc. | $3.180.738 | 252.640 | 1,69% | Aktien |
| ADAR1 Capital Management, LLC | $2.825.007 | 224.385 | 1,50% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $2.570.450 | 204.166 | 1,37% | Aktien |
| KENNEDY CAPITAL MANAGEMENT LLC | $2.570.160 | 204.143 | 1,37% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2.435.510 | 193.448 | 1,29% | Aktien |
| Ikarian Capital, LLC | $2.337.548 | 185.667 | 1,24% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $2.290.159 | 181.903 | 1,22% | Aktien |
| CIBC WORLD MARKET INC. | $2.054.789 | 163.208 | 1,09% | Aktien |
| Caption Management, LLC | $1.894.795 | 150.500 | 1,01% | Verkaufsoption |
| GOLDMAN SACHS GROUP INC | $1.885.353 | 149.750 | 1,00% | Aktien |
| Lane Generational LLC | $1.884.257 | 149.663 | 1,00% | Aktien |
| HSBC HOLDINGS PLC | $1.705.848 | 135.600 | 0,91% | Aktien |
| Man Group plc | $1.617.752 | 128.495 | 0,86% | Aktien |
| Cubist Systematic Strategies, LLC | $1.562.514 | 145.350 | 0,83% | Aktien |
| Diametric Capital, LP | $1.546.568 | 122.841 | 0,82% | Aktien |
| MORGAN STANLEY | $1.366.506 | 108.539 | 0,73% | Aktien |
| BARCLAYS PLC | $1.354.243 | 107.565 | 0,72% | Aktien |
| Caption Management, LLC | $1.259.000 | 100.000 | 0,67% | Kaufoption |
| Capital Advisors Wealth Management, LLC | $1.170.870 | 93.000 | 0,62% | Aktien |
| Jefferies Financial Group Inc. | $1.057.308 | 83.980 | 0,56% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $1.050.824 | 83.465 | 0,56% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.022.308 | 81.200 | 0,54% | Kaufoption |
| Stonepine Capital Management, LLC | $1.000.000 | 100.000 | 0,53% | Kaufoption |
| Caption Management, LLC | $978.243 | 77.700 | 0,52% | Aktien |
| FOX RUN MANAGEMENT, L.L.C. | $776.526 | 61.678 | 0,41% | Aktien |
| Quantbot Technologies LP | $749.860 | 59.560 | 0,40% | Aktien |
| D. E. Shaw & Co., Inc. | $728.885 | 57.894 | 0,39% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $725.864 | 57.654 | 0,39% | Aktien |
| Pale Fire Capital SE | $504.670 | 40.085 | 0,27% | Aktien |
| BANK OF AMERICA CORP /DE/ | $493.931 | 39.232 | 0,26% | Aktien |
| WOLVERINE TRADING, LLC | $479.600 | 44.000 | 0,25% | Kaufoption |
| RHUMBLINE ADVISERS | $458.822 | 36.444 | 0,24% | Aktien |
| ALPS ADVISORS INC | $441.154 | 35.040 | 0,23% | Aktien |
| EntryPoint Capital, LLC | $437.641 | 34.761 | 0,23% | Aktien |
| SEI INVESTMENTS CO | $394.936 | 31.369 | 0,21% | Aktien |
| AMERICAN CENTURY COMPANIES INC | $378.380 | 30.054 | 0,20% | Aktien |
| Balyasny Asset Management L.P. | $358.412 | 28.468 | 0,19% | Aktien |
| Leonteq Securities AG | $348.730 | 27.699 | 0,19% | Aktien |
| CITADEL ADVISORS LLC | $334.894 | 26.600 | 0,18% | Kaufoption |
| BOOTHBAY FUND MANAGEMENT, LLC | $319.484 | 25.376 | 0,17% | Aktien |
| Xcelsior Advisor Partners LLC | $318.527 | 25.300 | 0,17% | Aktien |
| Palisades Investment Partners, LLC | $293.007 | 23.273 | 0,16% | Aktien |
| WOLVERINE TRADING, LLC | $269.666 | 24.740 | 0,14% | Aktien |
| ALLIANCEBERNSTEIN L.P. | $239.424 | 25.800 | 0,13% | Aktien |
| MetLife Investment Management, LLC | $235.043 | 18.669 | 0,12% | Aktien |
| Bank of New York Mellon Corp | $234.942 | 18.661 | 0,12% | Aktien |
| WealthPlan Investment Management, LLC | $219.607 | 17.443 | 0,12% | Aktien |
| NOMURA HOLDINGS INC | $210.530 | 16.722 | 0,11% | Aktien |
| WOLVERINE TRADING, LLC | $209.280 | 19.200 | 0,11% | Verkaufsoption |
| CITADEL ADVISORS LLC | $202.699 | 16.100 | 0,11% | Verkaufsoption |
| CITADEL ADVISORS LLC | $189.391 | 15.043 | 0,10% | Aktien |
| SkyOak Wealth, LLC | $188.850 | 15.000 | 0,10% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $188.850 | 15.000 | 0,10% | Verkaufsoption |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $166.729 | 13.243 | 0,09% | Aktien |
| TUDOR INVESTMENT CORP ET AL | $151.609 | 12.042 | 0,08% | Aktien |
| LANARK FINANCIAL, INC. | $150.500 | 11.954 | 0,08% | Aktien |
| CITIGROUP INC | $146.485 | 11.635 | 0,08% | Aktien |
| Invesco Ltd. | $143.790 | 11.421 | 0,08% | Aktien |
| MERCER GLOBAL ADVISORS INC /ADV | $140.744 | 11.179 | 0,07% | Aktien |
| Nuveen, LLC | $138.754 | 11.021 | 0,07% | Aktien |
| Vanguard Global Advisers, LLC | $133.869 | 10.633 | 0,07% | Aktien |
| Schonfeld Strategic Advisors LLC | $131.136 | 10.416 | 0,07% | Aktien |
| LPL Financial LLC | $128.859 | 10.235 | 0,07% | Aktien |
| TWO SIGMA INVESTMENTS, LP | $126.580 | 10.054 | 0,07% | Aktien |
| Police & Firemen's Retirement System of New Jersey | $110.729 | 8.795 | 0,06% | Aktien |
| SHERBROOKE PARK ADVISERS LLC | $109.918 | 10.883 | 0,06% | Aktien |
| Hunting Hill Global Capital, LLC | $104.716 | 11.284 | 0,06% | Aktien |
| MARSHALL WACE, LLP | $84.177 | 6.686 | 0,04% | Aktien |
| FMR LLC | $69.144 | 5.492 | 0,04% | Aktien |
| Private Wealth Advisors, LLC | $62.950 | 5.000 | 0,03% | Kaufoption |
| NEW YORK STATE COMMON RETIREMENT FUND | $60.432 | 4.800 | 0,03% | Aktien |
| OSAIC HOLDINGS, INC. | $60.254 | 4.786 | 0,03% | Aktien |
| Point72 (DIFC) Ltd | $53.931 | 5.017 | 0,03% | Aktien |
| NORTHERN TRUST CORP | $53.797 | 4.273 | 0,03% | Aktien |
| Persistent Asset Partners Ltd | $52.954 | 4.206 | 0,03% | Aktien |
| Arax Advisory Partners | $51.884 | 4.121 | 0,03% | Aktien |
| IFP Advisors, Inc | $51.657 | 4.103 | 0,03% | Aktien |
| Integrated Wealth Concepts LLC | $48.145 | 3.824 | 0,03% | Aktien |
| Ameritas Investment Partners, Inc. | $38.714 | 3.075 | 0,02% | Aktien |
| Legal & General Group Plc | $34.534 | 2.743 | 0,02% | Aktien |
| CWM, LLC | $29.343 | 3.162 | 0,02% | Aktien |
| Creative Planning | $17.777 | 1.412 | 0,01% | Aktien |
| Tripletail Wealth Management, LLC | $16.632 | 1.260 | 0,01% | Aktien |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $14.950 | 1.611 | 0,01% | Aktien |
| AlphaQuest LLC | $14.473 | 1.433 | 0,01% | Aktien |
| Tower Research Capital LLC (TRC) | $13.711 | 1.089 | 0,01% | Aktien |
| Activest Wealth Management | $12.590 | 1.000 | 0,01% | Aktien |
| Geneos Wealth Management Inc. | $11.621 | 923 | 0,01% | Aktien |
Unternehmensinsider 46 Insider · 11 Führungskräfte · 16 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Jennifer K. Simpson | President and CEO | 8. Mai 2020 C | 25.021 | 0 | 0 | $0 |
| Barbra Keck | Chief Financial Officer, Secretary | 8. Mai 2020 C | 12.851 | 0 | 0 | $0 |
| Paul M Feinstein | Chief Financial Officer | 30. November 2007 A | 3.375 | 0 | 0 | $0 |
| John Purpura | Chief Operating Officer | 13. Oktober 2023 P | 41.526 | 0 | 0 | $0 |
| HERSCHKOWITZ SAMUEL /FA/ | Chief Operating Officer | 29. Mai 2007 P | 160.375 | 0 | 0 | $0 |
| Vojo Vukovic | Chief Medical Officer | 12. Dezember 2023 P | 100.000 | 0 | 0 | $0 |
| Sandra Pennell | SVP of Finance, PFO and PAO | 17. November 2023 P | 30.000 | 0 | 0 | $0 |
| David L. Hoffman | General Counsel, Chief Compliance Officer and Secretary | 16. November 2023 P | 40.000 | 0 | 0 | $0 |
| Kevin Muir | Vice President Commercial Operations | 12. Juni 2023 A | — | 0 | 0 | $0 |
| Johnny John | Senior Vice President Clinical Development and Medical Affairs | 12. Juni 2023 A | — | 0 | 0 | $0 |
| Christine Padula | Interim Principal Accounting Officer | 1. September 2021 A | — | 0 | 0 | $0 |
| John Richard Sylvester | Direktor | 21. August 2023 P | 10.550 | 0 | 0 | $0 |
| Aharon Gil | Direktor | 12. Juni 2023 A | 404.000 | 0 | 0 | $0 |
| Steven A J Salamon | Direktor | 12. Juni 2023 A | 440.100 | 0 | 0 | $0 |
| Roger G Stoll PHD | Direktor | 12. Juni 2023 A | 9.309 | 0 | 0 | $0 |
| Rosalind Advisors, Inc. | Direktor | 19. April 2022 P | 433.100 | 0 | 0 | $0 |
| Marco Taglietti | Direktor | 8. Mai 2020 C | 6.000 | 0 | 0 | $0 |
| William Dodge Rueckert | Direktor | 8. Mai 2020 C | 6.014 | 0 | 0 | $0 |
| Simon Pedder | Direktor | 1. Februar 2019 A | — | 0 | 0 | $0 |
| Laura A Philips | Direktor | 23. Juli 2015 P | 205.299 | 0 | 0 | $0 |
| Harold S Koplewicz | Direktor | 10. Juni 2015 A | 45.052 | 0 | 0 | $0 |
| Dennis Langer | Direktor | 10. Juni 2015 A | 20.000 | 0 | 0 | $0 |
| Jonathan Lewis | Direktor | 30. Juni 2008 A | 10.000 | 0 | 0 | $0 |
| Mark Corigliano | Direktor | 16. April 2007 M | 198.176 | 0 | 0 | $0 |
| Daniel Isdaner | Direktor | 16. April 2007 M | 253.668 | 0 | 0 | $0 |
| Elizabeth Czerepak | — | 13. Mai 2026 A | — | 0 | 0 | $0 |
| Gerard J Michel | — | 2. März 2026 P | 342.034 | 2 | 0 | $198.447 |
| Laura Brege | — | 7. Juli 2014 A | 11.678 | 0 | 0 | $0 |
| Tasos Konidaris | — | 7. Juli 2014 A | 11.678 | 0 | 0 | $0 |
| Gabriel Leung | — | 7. Juli 2014 A | 21.485 | 0 | 0 | $0 |
| Douglas G Watson | — | 7. Juli 2014 A | 136.664 | 0 | 0 | $0 |
| Graham G Miao | — | 14. November 2013 A | 54.000 | 0 | 0 | $0 |
| Peter J Graham | — | 14. November 2013 A | 15.000 | 0 | 0 | $0 |
| William M Appling | — | 15. Juli 2013 A | — | 0 | 0 | $0 |
| Krishna Kandarpa | — | 11. März 2013 A | 159.000 | 0 | 0 | $0 |
| Harold Mapes | — | 11. März 2013 A | 17.000 | 0 | 0 | $0 |
| Eamonn P Hobbs | — | 11. März 2013 A | 162.000 | 0 | 0 | $0 |
| Agustin V Gago | — | 11. März 2013 A | 80.944 | 0 | 0 | $0 |
| Robert Ladd | — | 15. Juni 2012 A | 69.534 | 0 | 0 | $0 |
| David Mcdonald | — | 10. März 2011 A | 47.706 | 0 | 0 | $0 |
| Pamela Reilly Contag | — | 1. Dezember 2010 A | 8.507 | 0 | 0 | $0 |
| Richard Taney | — | 10. Dezember 2009 A | 211.485 | 0 | 0 | $0 |
| Jason Andrew Rifkin | — | 12. Oktober 2009 A | — | 0 | 0 | $0 |
| KOLY M S /FA/ | — | 26. Januar 2007 X | 775.360 | 0 | 0 | $0 |
| Victor Nevins | — | 12. Oktober 2006 M | 180.007 | 0 | 0 | $0 |
| VENKOL TRUST | — | 10. November 2004 J | 892.649 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
Aktivisten & 5%+-Eigentümer 17 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Rosalind Advisors, Inc., SALAMON STEVEN A J, Aharon Gil, Rosalind Master Fund L.P., Rosalind Opportunities Fund I L.P. ×15 Einreichungen | 10. Februar 2026 | 9,90% | Änderung | — | SEC |
| Nicht offengelegter meldender Beteiligter | 16. Dezember 2022 | — | Erste Einreichung | Passive Anlage | SEC |
| Nicht offengelegter meldender Beteiligter | 27. Juli 2022 | — | Erste Einreichung | Passive Anlage | SEC |
| Laddcap Value Partners LP S.S. or, Laddcap Value Associates LLC S.S. or, Laddcap Value Advisors LLC S.S. or, Robert Ladd S.S. or ×2 Einreichungen | 2. August 2010 | — | Erste Einreichung | — | SEC |
| Robert Ladd | 18. Oktober 2006 | — | Erste Einreichung | Passive Anlage | SEC |
| Nicht offengelegter meldender Beteiligter | 28. Juli 2006 | — | Erste Einreichung | Vorstandskampagne | SEC |
| Nicht offengelegter meldender Beteiligter | 11. Juli 2006 | — | Erste Einreichung | — | SEC |
| Nicht offengelegter meldender Beteiligter | 14. Juni 2006 | — | Erste Einreichung | — | SEC |
| Nicht offengelegter meldender Beteiligter | 8. Juni 2006 | — | Erste Einreichung | — | SEC |
| Nicht offengelegter meldender Beteiligter | 24. Mai 2006 | — | Erste Einreichung | — | SEC |
| Nicht offengelegter meldender Beteiligter | 28. April 2006 | — | Erste Einreichung | — | SEC |
| Nicht offengelegter meldender Beteiligter | 10. Januar 2006 | — | Erste Einreichung | — | SEC |
| Nicht offengelegter meldender Beteiligter | 6. Januar 2006 | — | Erste Einreichung | — | SEC |
| Nicht offengelegter meldender Beteiligter | 14. Dezember 2005 | — | Erste Einreichung | — | SEC |
| Nicht offengelegter meldender Beteiligter | 10. November 2005 | — | Erste Einreichung | Vorstandskampagne | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF-Besitz Gehalten von 22 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| SBIO · ALPS ETF Trust | 0,24% | 35.814 NS | 31. Mai 2026 | N-PORT |
| GSSC · Goldman Sachs ETF Trust | 0,04% | 35.321 NS | 31. Mai 2026 | N-PORT |
| RSSL · Global X Funds | 0,01% | 13.080 NS | 30. April 2026 | N-PORT |
| AVSC · AMERICAN CENTURY ETF TRUST | 0,01% | 22.609 NS | 31. Mai 2026 | N-PORT |
| ITWO · ProShares Trust | 0,01% | 1.420 NS | 31. Mai 2026 | N-PORT |
| UWM · ProShares Trust | 0,00% | 1.111 NS | 31. Mai 2026 | N-PORT |
| URTY · ProShares Trust | 0,00% | 1.122 NS | 31. Mai 2026 | N-PORT |
| MSSM · MORGAN STANLEY PATHWAY FUNDS | 0,00% | 1.638 NS | 31. Mai 2026 | N-PORT |
| HDG · ProShares Trust | 0,00% | 28 NS | 31. Mai 2026 | N-PORT |
| DFAS · Dimensional ETF Trust | 0,00% | 19.222 NS | 30. April 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | — | — | 15. Juli 2026 | Täglich |
| VTI · VANGUARD INDEX FUNDS | — | — | 15. Juli 2026 | Täglich |
| VTWO · VANGUARD SCOTTSDALE FUNDS | — | — | 15. Juli 2026 | Täglich |
| VTWV · VANGUARD SCOTTSDALE FUNDS | — | — | 15. Juli 2026 | Täglich |
| VTWG · VANGUARD SCOTTSDALE FUNDS | — | — | 15. Juli 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | — | — | 15. Juli 2026 | Täglich |
| ITOT · iShares Trust | — | — | 22. Juli 2026 | Täglich |
| IWN · iShares Trust | — | — | 17. August 2026 | Täglich |
| IWO · iShares Trust | — | — | 18. August 2026 | Täglich |
| IWM · iShares Trust | — | — | 18. August 2026 | Täglich |
| IWC · iShares Trust | — | — | 18. August 2026 | Täglich |
| OMFS · Invesco Exchange-Traded Self-Indexe… | — | — | 13. Juli 2026 | Täglich |